Table 1.
Clinical Characteristics
| Variable | Overall (n = 80) | IDH mutant (n = 59) | IDH NOS (n = 21) |
|---|---|---|---|
| Age, median (IQR) | 47.2 (37.6–56.3) | 49.5 (37.7–57.9) | 42.6 (37.6–49.1) |
| Female sex, n (%) | 31 (38.8%) | 21 (35.6%) | 10 (47.6%) |
| Location, n (%) | |||
| Frontal | 63 (78.9%) | 45 (76.3%) | 18 (85.7%) |
| Parietal | 12 (15.0%) | 8 (13.6%) | 4 (19.0%) |
| Temporal | 9 (11.3%) | 8 (13.6%) | 1 (4.8%) |
| Occipital | 3 (3.8%) | 3 (5.1%) | 0 (0.0%) |
| Other | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Radiographic features, n (%) | |||
| T1 contrast enhancement | 43 (53.8%) | 32 (54.2%) | 11 (52.4%) |
| Diffusion restriction | 16 (20.0%) | 11 (18.6%) | 5 (23.8%) |
| Extent of resection, n (%) | |||
| Biopsy | 3 (3.8%) | 3 (5.1%) | 0 (0.0%) |
| Subtotal resection | 56 (70.0%) | 41 (69.5%) | 15 (71.4%) |
| Gross total resection | 21 (26.3%) | 15 (25.4%) | 6 (28.6%) |
| Adjuvant chemotherapy, n (%) | 76 (95.0%) | 56 (94.9%) | 20 (95.2%) |
| Adjuvant radiation therapy, n (%) | 55 (68.8%) | 42 (71.2%) | 13 (61.9%) |
| Progression, n (%) | 43 (53.8%) | 29 (49.2%) | 14 (66.7%) |
IDH, isocitrate dehydrogenase; IQR, interquartile range; NOS, not otherwise specified.